Clinical Trial Update: Observational Study of Golimumab Intravenous Infusion

View source ↗

Summary

An observational study of intravenous golimumab for rheumatoid arthritis has been terminated. The sponsor is Janssen Inc., and the document provides the status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Janssen Inc. | Conditions: Rheumatoid Arthritis | Status: TERMINATED